Hodgkin’s lymphoma is caused by malfunctioning lymphocytes, white blood cells that usually help our bodies fight infection. It is much less common than the other main type of lymphoma, non-Hodgkin’s lymphoma. An estimated 9,000 new cases of Hodgkin’s lymphoma are diagnosed in the United States each year. Hodgkin’s lymphoma can be cured or controlled for many years in most people who have the disease.
Better Survival Rates for Lymphoma
Studies have shown that the first treatment you receive for cancer is by far the most important. On average, lymphoma patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere.
Precision Medicine, Including Clinical Studies
As a patient of SCCA, you receive expertly targeted and delivered care, tailored to your specific type, subtype, and stage of lymphoma. Through SCCA, you have access to the full spectrum of lymphoma treatments, including advanced therapies being explored in clinical studies for lymphoma conducted through SCCA and its founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
Greatest Experience with Bone Marrow Transplants
For people with lymphoma who are good candidates for stem cell transplants, the Fred Hutchinson Transplant program at SCCA is the most experienced transplant program in the world. It ranked first in outcomes in a multi-year study by the National Marrow Donor Program that measured one-year survival rates of patients at 122 transplant centers nationwide.
Doctors with Leading-Edge Expertise
SCCA patients diagnosed with Hodgkin’s lymphoma receive state-of-the-art care from a team of specialists, including:
- Medical oncologists who specialize in targeted therapies and advanced chemotherapy treatments
- Hematopathologists expert in identifying lymphomas in biopsied tissue
- Radiation oncologists who have special expertise in targeted radiation therapy
- Experienced transplant specialists at the center that pioneered bone marrow transplantation as a treatment for blood diseases more than 40 years ago